share_log

JP Morgan Maintains Overweight on Neumora Therapeutics, Lowers Price Target to $20

Benzinga ·  Nov 8, 2023 15:32

JP Morgan analyst Tessa Romero maintains Neumora Therapeutics (NASDAQ:NMRA) with a Overweight and lowers the price target from $21 to $20.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment